Cepharanthine and Piperine ameliorate diabetic nephropathy in rats: role of NF-κB and NLRP3 inflammasome

Life Sciences

Volumn 157, Issue , 2016, Pages 187-199

  Samra, Yara A ^a   Said, Heba S ^a   Elsherbiny, Nehal M ^a   Liou, Gregory I ^b   El Shishtawy, Mamdouh M ^a   Eissa, Laila A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cepharanthine; Diabetes; NF B; NLRP3; Piperine; Renal injury; TXNIP

Indexed keywords

CEPHARANTHINE; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MALONALDEHYDE; PIPERINE; THIOREDOXIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; BENZYLISOQUINOLINE DERIVATIVE; INFLAMMASOME; NLRP3 PROTEIN, RAT; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; KIDNEY INJURY; KIDNEY MASS; KIDNEY PARENCHYMA; MALE; METABOLIC PARAMETERS; NONHUMAN; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; UREA NITROGEN BLOOD LEVEL; ANIMAL; DIABETIC NEPHROPATHIES; METABOLISM; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; BENZODIOXOLES; BENZYLISOQUINOLINES; DIABETIC NEPHROPATHIES; INFLAMMASOMES; MALE; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84975885980     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.06.002     Document Type: Article

References (66)

1. [1] Luis-Rodrı'guez, D., Martı'nez-Castelao, A., Go'rriz, J.L., De-A' lvaro, F., Navarro-Gonza'lez, J.F., Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J. Diabetes 3 (2012), 7–18, 10.4239/wjd.v3.i1.7.
2. [2] Zhou, X., Wang, B., Zhu, L., Hao, S., A novel improved therapy strategy for diabetic nephropathy: targeting AGEs. Organogenesis 8 (2012), 18–21, 10.4161/org.19332.
3. [3] Palsamy, P., Subramanian, S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta 2011 (1812), 719–731, 10.1016/j.bbadis.2011.03.008.
4. [4] Gariani, K., de Seigneux, S., Pechere-Bertschi, A., Philippe, J., Martin, P.Y., Diabetic nephropathy: an update. Rev. Med. Suisse 8 (2012), 473–479.
5. [5] Svensson, M., Sundkvist, G., Arnqvist, H.J., Björk, E., Blohmé, G., Bolinder, J., Henricsson, M., Nyström, L., Torffvit, O., Waernbaum, I., Ostman, J., Eriksson, J.W., Diabetes incidence study in Sweden (DISS). Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based diabetes incidence study in Sweden (DISS). Diabetes Care 26 (2003), 2903–2909.
6. [6] Mariathasan, S., Newton, K., Monack, D.M., Vucic, D., French, D.M., Lee, W.P., Roose-Girma, M., Erickson, S., Dixit, V.M., Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430 (2004), 213–218.
7. [7] Pétrilli, V., Dostert, C., Muruve, D.A., Tschopp, J., The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19 (2007), 615–622.
8. [8] Gao, P., Meng, X.F., Su, H., He, F.F., Chen, S., Tang, H., Tian, X.J., Fan, D., Wang, Y.M., Liu, J.S., Zhu, Z.H., Zhang, C., Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy. Biochim. Biophys. Acta 2014 (1843), 2448–2460, 10.1016/j.bbamcr.2014.07.001.
9. [9] Turner, C.M., Arulkumaran, N., Singer, M., Unwin, R.J., Tam, F.W., Is the inflammasome a potential therapeutic target in renal disease?. BMC Nephrol., 15, 2014, 21, 10.1186/1471-2369-15-21.
10. [10] Patwari, P., Higgins, L.J., Chutkow, W.A., Yoshioka, J., Lee, R.T., The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J. Biol. Chem. 281 (2006), 21884–21891.
11. [11] Schulze, P.C., Yoshioka, J., Takahashi, T., He, Z., King, G.L., Lee, R.T., Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J. Biol. Chem. 279 (2004), 30369–30374.
12. [12] Tan, C.Y., Weier, Q., Zhang, Y., Cox, A.J., Kelly, D.J., Langham, R.G., Thioredoxin-interacting protein: a potential therapeutic target for treatment of progressive fibrosis in diabetic nephropathy. Nephron 129 (2015), 109–127, 10.1159/000368238.
13. [13] Oslowski, C.M., Hara, T., O'Sullivan-Murphy, B., Kanekura, K., Lu, S., Hara, M., Ishigaki, S., Zhu, L.J., Hayashi, E., Hui, S.T., Greiner, D., Kaufman, R.J., Bortell, R., Urano, F., Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab. 16 (2012), 265–273, 10.1016/j.cmet.2012.07.005.
14. [14] Srinivasan, K., Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit. Rev. Food Sci. Nutr. 47 (2007), 735–748.
15. [15] Lee, E.B., Shin, K.H., Woo, W.S., Pharmacological study on piperine. Arch. Pharm. Res. 7 (1984), 127–132, 10.1007/BF02856625.
16. [16] Pathak, N., Khandelwal, S., Cytoprotective and immunomodulating properties of piperine on murine splenocytes: an in vitro study. Eur. J. Pharmacol. 576 (2007), 160–170.
17. [17] Bang, J.S., Oh da, H., Choi, H.M., Sur, B.J., Lim, S.J., Kim, J.Y., Yang, H.I., Yoo, M.C., Hahm, D.H., Kim, K.S., Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1β-stimulated fibroblast-like synoviocytes and in rat arthritis models. Arthritis Res. Ther., 11, 2009, R49, 10.1186/ar2662.
18. [18] Umar, S., Golam Sarwar, A.H., Umar, K., Ahmad, N., Sajad, M., Ahmad, S., Katiyar, C.K., Khan, H.A., Piperine ameliorates oxidative stress, inflammation and histological outcome in collagen induced arthritis. Cell. Immunol. 284 (2013), 51–59, 10.1016/j.cellimm.2013.07.004.
19. [19] Bun, S.S., Laget, M., Chea, A., Bun, H., Ollivier, E., Elias, R., Cytotoxic activity of alkaloids isolated from Stephania rotunda [corrected]. Phytother. Res. 23 (2009), 587–590, 10.1002/ptr.2617.
20. [20] Kudo, K., Hagiwara, S., Hasegawa, A., Kusaka, J., Koga, H., Noguchi, T., Cepharanthine exerts anti-inflammatory effects via NF-kappaB inhibition in a LPS-induced rat model of systemic inflammation. J. Surg. Res. 171 (2011), 199–204, 10.1016/j.jss.2010.01.007.
21. [21] Elsherbiny, N.M., Abd El Galil, K.H., Gabr, M.M., Al-Gayyar, M.M., Eissa, L.A., El-Shishtawy, M.M., Reno- protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur. Cytokine Netw. 23 (2012), 78–86, 10.1684/ecn.2012.0309.
22. [22] Murunikkara, V., Pragasam, S.J., Kodandaraman, G., Sabina, E.P., Rasool, M., Anti-inflammatory effect of piperine in adjuvant-induced arthritic rats–a biochemical approach. Inflammation 35 (2012), 1348–1356, 10.1007/s10753-012-9448-3.
23. [23] de Cavanagh, E.M., Inserra, F., Ferder, L., Fraga, C.G., Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am. J. Phys. Regul. Integr. Comp. Phys. 278 (2000), R572–R577.
24. [24] Bagheri, F., Gol, A., Dabiri, S., Javadi, A., Preventive effect of garlic juice on renal reperfusion injury. Iran. J. Kidney Dis. 5 (2011), 194–200.
25. [25] Kelly, D.J., Edgley, A.J., Zhang, Y., Thai, K., Tan, S.M., Cox, A.J., Advani, A., Connelly, K.A., Whiteside, C.I., Gilbert, R.E., Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrol. Dial. Transplant. 24 (2009), 1782–1790, 10.1093/ndt/gfn729.
26. [26] Lee, H.B., Yu, M.R., Yang, Y., Jiang, Z., Ha, H., Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (2003), S241–S245.
27. [27] Liu, Y., Shepherd, E.G., Nelin, L.D., MAPK phosphatases–regulating the immune response. Nat. Rev. Immunol. 7 (2007), 202–212.
28. [28] Navarro, J.F., Mora, C., Role of inflammation in diabetic complications. Nephrol. Dial. Transplant. 20 (2005), 2601–2604, 10.1093/ndt/gfi155.
29. [29] Wolkow, P.P., Niewczas, M.A., Perkins, B., Ficociello, L.H., Lipinski, B., Warram, J.H., Krolewski, A.S., Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J. Am. Soc. Nephrol. 19 (2008), 789–797, 10.1681/ASN.2007050556.
30. [30] Rang, H.P., Dale, M.M., Ritter, H.M., Gardner, P., Pharmacology. fifth ed., 2003, Churchill Livingstone, Edinburgh, UK, 163.
31. [31] Klein, J., Fasshauer, M., Benito, M., Kahn, C.R., Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. Mol. Endocrinol. 14 (2000), 764–773.
32. [32] Sharma, H.L., Sharma, K.K., Principles of Pharmacology. first ed., 2008, Paras Medical Publishers, New Delhi, 653.
33. [33] Shah, S., Shah, G., Patel, M.B., Singh, S., Effect of piperine in obesity induced insulin resistance and type_II diabetes mellitus in rats. J. Nat. Remedies 10 (2010), 116–122.
34. [34] Inui, S., Itami, S., Induction of insulin-like growth factor-I by cepharanthine from dermal papilla cells: a novel potential pathway for hair growth stimulation. J. Dermatol. 40 (2013), 1054–1055, 10.1111/1346-8138.
35. [35] Dunger, D.B., Cheetham, T.D., Crowne, E.C., Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44 (1995), 119–123.
36. [36] Zenobi, P.D., Jaeggi-Groisman, S.E., Riesen, W.F., Røder, M.E., Froesch, E.R., Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J. Clin. Invest. 90 (1992), 2234–2241.
37. [37] Singh, D.K., Winocour, P., Farrington, K., Oxidative stress in early diabetic nephropathy: fueling the fire. Nat. Rev. Endocrinol. 7 (2011), 176–184, 10.1038/nrendo.2010.212.
38. [38] Navarro-Gonza'lez, J.F., Mora-Ferna'ndez, C., Muros de Fuentes, M., Garcı'a-Pe'rez, J., Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7 (2011), 327–340, 10.1038/nrneph.2011.51.
39. [39] Ahmad, J., Management of diabetic nephropathy: recent progress and future perspective. Diabetol. Metab. Syndr., 2015, 10.1016/j.dsx.2015.02.008 pii:(S1871-4021(15) 00021-1).
40. [40] Halicka, D., Ita, M., Tanaka, T., Kurose, A., Darzynkiewicz, Z., Biscoclaurine alkaloid cepharanthine protects DNA in TK6 lymphoblastoid cells from constitutive oxidative damage. Pharmacol. Rep. 60 (2008), 93–100.
41. [41] Mittal, R., Gupta, R.L., In vitro antioxidant activity of piperine. Methods Find. Exp. Clin. Pharmacol. 22 (2000), 271–274.
42. [42] Meyer, M., Schreck, R., Baeuerle, P.A., H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12 (1993), 2005–2015.
43. [43] Lim, A.K., Tesch, G.H., Inflammation in diabetic nephropathy. Mediat. Inflamm., 2012, 2012, 146154, 10.1155/2012/146154.
44. [44] Pickup, J.C., Chusney, G.D., Thomas, S.M., Burt, D., Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci. 67 (2000), 291–300.
45. [45] Bruno, G., Merletti, F., Biggeri, A., Bargero, G., Ferrero, S., Pagano, G., Cavallo Perin, P., Study, C.M., Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato study. Diabetes Care 26 (2003), 2150–2155.
46. [46] Feng, J., Guo, C., Zhu, Y., Pang, L., Yang, Z., Zou, Y., Zheng, X., Baicalin down regulates the expression of TLR4 and NFkB-p65 in colon tissue in mice with colitis induced by dextran sulfate sodium. Int. J. Clin. Exp. Med. 7 (2014), 4063–4072.
47. [47] Abo El-Magd, N.F., El-Karef, A., El-Shishtawy, M.M., Eissa, L.A., Hepatoprotective effects of glycyrrhizin and omega-3 fatty acids on nuclear factor-kappa B pathway in thioacetamide-induced fibrosis in rats. Egypt. J. Basic Appl. Sci. 2 (2015), 65–74, 10.1016/j.ejbas.2014.12.005.
48. [48] Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, E., Bleich, M., Grِne, H.J., Nelson, P.J., Schlِndorff, D., Cohen, C.D., Kretzler, M., European Renal cDNA Bank (ERCB) Consortium, Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55 (2006), 2993–3003.
49. [49] Soetikno, V., Sari, F.R., Veeraveedu, P.T., Thandavarayan, R.A., Harima, M., Sukumaran, V., Lakshmanan, A.P., Suzuki, K., Kawachi, H., Watanabe, K., Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr. Metab. (Lond.), 8, 2011, 35, 10.1186/1743-7075-8-35.
50. [50] Popa, C., Netea, M.G., van Riel, P.L., van der Meer, J.W., Stalenhoef, A.F., The role of TNFalpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 48 (2007), 751–762, 10.1194/jlr.R600021-JLR200.
51. [51] Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., Spiegelman, B.M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF alpha- and obesity induced insulin resistance. Science 271 (1996), 665–668.
52. [52] Lang, C.H., Dobrescu, C., Bagby, G.J., Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130 (1992), 43–52.
53. [53] Whitmarsh, A.J., Davis, R.J., Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. (Berl) 74 (1996), 589–607.
54. [54] Haneda, M., Araki, S., Togawa, M., Sugimoto, T., Isono, M., Kikkawa, R., Activation of mitogen-activated protein kinase cascade in diabetic glomeruli and mesangial cells cultured under high glucose conditions. Kidney Int. Suppl. 60 (1997), S66–S69.
55. [55] Lakshmanan, A.P., Thandavarayan, R.A., Watanabe, K., Sari, F.R., Meilei, H., Giridharan, V.V., Sukumaran, V., Soetikno, V., Arumugam, S., Suzuki, K., Kodama, M., Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol. Cell. Endocrinol. 348 (2012), 104–111, 10.1016/j.mce.2011.07.041.
56. [56] Goebeler, M., Gillitzer, R., Kilian, K., Utzel, K., Brِcker, E.B., Rapp, U.R., Ludwig, S., Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 97 (2001), 46–55.
57. [57] Pan, Y., Zhang, X., Wang, Y., Cai, L., Ren, L., Tang, L., Wang, J., Zhao, Y., Wang, Y., Liu, Q., Li, X., Liang, G., Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice. PLoS One, 8, 2013, e79084, 10.1371/journal.pone.0079084.
58. [58] Pradhan, A., Umezu, M., Fukagawa, M., Heme-oxygenase upregulation ameliorates angiotensin II-induced tubulointerstitial injury and salt-sensitive hypertension. Am. J. Nephrol. 26 (2006), 552–561.
59. [59] Tesch, G.H., Macrophages and diabetic nephropathy. Semin. Nephrol. 30 (2010), 290–301, 10.1016/j.semnephrol.2010.03.007.
60. [60] MacKenzie, A., Wilson, H.L., Kiss-Toth, E., Dower, S.K., North, R.A., Surprenant, A., Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15 (2001), 825–835.
61. [61] Nishinaka, Y., Masutani, H., Oka, S., Matsuo, Y., Yamaguchi, Y., Nishio, K., Ishii, Y., Yodoi, J., Importin alpha1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D(3)-up-regulated protein 1. J. Biol. Chem. 279 (2004), 37559–37565.
62. [62] Fang, S., Jin, Y., Zheng, H., Yan, J., Cui, Y., Bi, H., Jia, H., Zhang, H., Wang, Y., Na, L., Gao, X., Zhou, H., High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway. Mol. Cell. Biochem. 347 (2011), 175–182, 10.1007/s11010-010-0626-z.
63. [63] Qi, W., Chen, X., Gilbert, R.E., Zhang, Y., Waltham, M., Schache, M., Kelly, D.J., Pollock, C.A., High glucose-induced thioredoxin interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am. J. Pathol. 171 (2007), 744–754.
64. [64] Advani, A., Gilbert, R.E., Thai, K., Gow, R.M., Langham, R.G., Cox, A.J., Connelly, K.A., Zhang, Y., Herzenberg, A.M., Christensen, P.K., Pollock, C.A., Qi, W., Tan, S.M., Parving, H.H., Kelly, D.J., Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J. Am. Soc. Nephrol. 20 (2009), 730–741, 10.1681/ASN.2008020142.
65. [65] Mohamed, I.N., Hafez, S.S., Fairaq, A., Ergul, A., Imig, J.D., El-Remessy, A.B., Thioredoxin interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia 57 (2014), 413–423, 10.1007/s00125-013-3101-z.
66. [66] Zhou, R., Tardivel, A., Thorens, B., Choi, I., Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140, 10.1038/ni.1831.